ORGANIZATIONS A different context for teaching about fraud Mary Anne Atkinson Cheryl Prachyl Carol Sullivan American Accounting Association Annual Meeting Atlanta Georgia August 2014 ID: 289835
Download Presentation The PPT/PDF document "FRAUD IN HEALTHCARE" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
FRAUD IN HEALTHCARE ORGANIZATIONS:(A different context for teaching about fraud)
Mary Anne Atkinson
Cheryl
Prachyl
Carol
Sullivan
American Accounting Association Annual Meeting
Atlanta, Georgia August 2014Slide2
Why exposing students to these cases is important.Healthcare fraud losses are estimated to be about 80 billion dollars per
year.
These losses contribute to rapidly increasing healthcare costs for all Americans.
Healthcare fraud differs from the types of fraud that accounting students generally study. Reviewing healthcare fraud cases can expand students’ knowledge of
how different types of healthcare fraud might be perpetrated and
the extensive list of stakeholders involved when healthcare fraud is committed. Slide3
Suggested Classroom UseReview cases and discuss how the frauds might be perpetrated and/or discovered.Discuss ethical issues including determining the stakeholders, impacts of the frauds, and possible rationalizations of the perpetrators.
Consider possible control mechanisms that might be used to prevent such frauds and discuss how these controls might impact patients, health care providers, and businesses involved in delivering heath care products and services.
Discuss perpetrators and how they differ from those who commit financial frauds.Slide4
Appropriate ClassesAccounting Information Systems – especially in considering controls and detection methodsEthics – Useful in helping students recognize the broad range of stakeholders who may be affected by fraud.
Introductory Financial – Provide a good introduction to the concept of fraud and stakeholder identification. Slide5
Who Commits Health Care Fraud?Slide6
Example Provider Fraud MethodsBilling for services not performed
Billing duplicate times for one service performed
Falsifying a diagnosis
Misrepresenting procedures (billing for a covered service when a non-covered service was performed)
Upcoding
– billing for a more costly service than was performed
Accepting kickbacks for patient referrals
Waiving co-pays or deductible amounts and overbilling insurance planSlide7
Healthcare Spending in PerspectiveHealthcare spending in 2011 was $2.7 billion. This represents 17.9%
of
Gross
Domestic Product (GDP) – a significant increase from the 1970 health care
spending of 7.2
% of the GDP.
A
2013 study reported that about 25% of all senior citizens declare bankruptcy due to medical expenses and 43% either mortgage or sell their primary residence because of financial problems.
Healthcare fraud impacts the economy as well as individuals.Slide8
Where To Find CasesA good resource to identify cases of healthcare fraud is the Department of Justice web site
http
://www.justice.gov
/
The site can be searched by company name and will provide details of allegations against companies as well as settlements that may have been reached.
The information provided there is brief enough that the readings could be used in class to foster discussion of various topics related to fraud and/or ethics.Slide9
Case ExamplesGlaxo Smith-K
line
Purdue
F
rederick Company
Bristol-Myers Squibb
Company
Amerigroup
Pfizer
Sanofi-
Aventis
WellCare
Health Plans, Inc
.
Amgen Inc
.
Johnson & Johnson
Wyeth
Genzyme
RehabCare
Group, Inc.
VA HospitalSlide10
Glaxo Smith-
K
line
In 2006,
Glaxo
Smith-Kline paid $14 million to settle charges of patient fraud and related violations. They were found to have attempted to block the generic versions of their antidepressant drug Paxil from reaching the market.
In 2010,
Glaxo
Smith-Kline pled guilty to charges related to the manufacture and distribution of certain adulterated drugs and paid a $600 million civil settlement as well as another $150 million in criminal finds and forfeiture. Slide11
Purdue Frederick CompanyThe government alleged that Purdue fraudulently misbranded OxyContin as being less addictive and less subject to abuse than other pain medications.
The company pled
guilty to charges of misbranding the addictive and highly
abusable
drug in 2007.
Purdue
forfeited $276.1 million to the United States (about $160 million to resolve liability for false claims made to Medicaid and other government healthcare programs) and paid a total of $634.5 million as a global resolution for their criminal and civil liabilities.Slide12
Bristol-Myers Squibb Company
In
2007, Bristol-Myers Squibb (BMS) paid the United States $328 million
and
$187 million to state governments to
resolve allegations related to illegal drug pricing and marketing activities for its generic division,
Apothecon
.
The
allegations were that
(
1) BMS and
Apothecon
set and maintained inflated prices
(2) BMS paid kickbacks to doctors to induce them to purchase BMS’s drugs;
(
3) BMS paid kickbacks to wholesalers and retail pharmacies to induce purchases of generic products;
(
4) BMS promoted
Abilify
, for
uses
that were not approved by the Food and Drug Administration (FDA
)
(
5) BMS violated the Medicaid Drug Rebate
Act by
reporting false “best prices” to
the
government
which
resulted in BMS underpaying quarterly rebates owed to the Medicaid program. Slide13
AmerigroupAmerigroup was contracted to provide managed health care to all eligible low income individuals in Illinois. The
corporation was alleged to have avoided enrolling pregnant women and unhealthy individuals in its managed care program, thereby cutting its costs and increasing its profits.
In 2008,
Amerigroup
Corporation agreed to pay $225 million to resolve allegations that it defrauded the Illinois Medicaid system. Slide14
Pfizer
Pfizer
pleaded guilty
in 2009 to
charges of misbranding several drugs with the intent to mislead or defraud:
Bextra
, Geodon,
Zyvox
, and
Lyrica
.
Pfizer
promoted the use of these drugs for “off-label” purposes
.
Pfizer
also was charged with paying kickbacks to health care providers to induce them to prescribe the drugs.
Pfizer
agreed to pay $2.3 billion to settle the
charges
and
Pfizer
subsidiary Pharmacia & Upjohn will pay a $1.195 billion criminal fine
for similar
charges
for
the unapproved use of their drug
Neurontin.Slide15
Sanofi-Aventis
In 2009, Sanofi-Aventis paid $95 million to settle charges that it misrepresented drug prices in the Medicaid Drug Rebate Program. Slide16
WellCare Health Plans, Inc.WellCare
Health Plans agreed to a settlement of $80 million for claims that the firm overcharged the Florida Medicaid program for behavioral health services.
The
fraud was perpetrated through the creation of an intermediary entity that increased service expenses to equal the amounts paid by insurers for those
services
In
2012,
WellCare
Health Plans, Inc., agreed to pay $137.5 million to resolve FCA allegations that
WellCare
had falsely inflated claimed expenses in order to avoid returning money to Medicaid, falsified patient records, knowingly retained overpayments, and engaged in marketing abuses by cherry-picking healthy patients. Slide17
Amgen Inc.In 2012, Amgen Inc. agreed to pay $762 million to resolve criminal and FCA liability related to the marketing and promotion of certain drugs.
Amgen
agreed to pay $612 million to resolve civil FCA allegations that Amgen engaged in off-label promotion for uses and doses that were not approved by the FDA, offering kickbacks to healthcare providers, and false price reporting practices. Slide18
Johnson & JohnsonPaying kickbacks to physicians and pharmacies to recommend and prescribe Risperdal and
Invega
(antipsychotic drugs) as well as
Natrecor
(used to treat heart failure) were the allegations.
In
November 2013, Johnson & Johnson agreed to pay over $2.2 billion to resolve criminal and civil allegations of promoting three prescription drugs for off-label uses not approved by the Food and Drug Administration. Slide19
WyethWyeth illegally
marketed
a transplant drug called
Rapamune
for uses that had not been approved by the Food and Drug Administration.
In
2013, Pfizer, Inc., who owns Wyeth, will pay $257 million
to
resolve civil allegations that Wyeth engaged in illegal marketing and will pay another $234 million of the settlement
to
cover criminal fines and penalties. Slide20
Genzyme Corp.In 2013, Genzyme Corp. agreed to pay $22.28 million to resolve allegations that it marketed and caused false claims to be submitted to federal and state health care programs for use of a “slurry” version of its
Seprafilm
adhesion barrier. Slide21
Rehabcare Group, Inc.In 2014, nationwide contract therapy providers,
RehabCare
Group, Inc. agreed to pay $30 million to resolve the claims that they violated the False Claims Act by engaging in a kickback scheme related to the referral of nursing home business.Slide22
VA HospitalAudit reports released in 2014 indicate that schedulers falsified records to conceal wait times for veterans to receive initial primary care appointments.
The push to falsify the wait times are likely related to tying bonuses and salary increases to decreased wait times.